New Clinical Trial for Prostate Cancer Treatment

HP518 tau raug tshawb pom thiab tsim los ntawm Hinova lub hom phiaj cov tshuaj tiv thaiv kev puas tsuaj rau kev tshawb pom platform. Nws muaj peev xwm kov yeej cov tshuaj tiv thaiv ntawm prostate cancer vim qee qhov kev hloov pauv AR.

Chimeric degraders yog bifunctional me me molecules uas txhawb kev degradation ntawm lub hom phiaj proteins nrog siab potency thiab siab selectivity. Cov thev naus laus zis no muaj peev xwm los tsom cov hom phiaj uas tsis yog siv tshuaj thiab kov yeej qhov teeb meem tshuaj tiv thaiv ntawm cov tshuaj me me molecule.

"Qhov no yog lub sijhawm tseem ceeb hauv kev nce qib ntawm peb cov kev siv zog los ntawm kev tshawb nrhiav tshuaj rau kev tshawb fawb soj ntsuam," said Yuanwei Chen, Ph.D., Thawj Tswj Hwm thiab CEO ntawm Hinova. "Peb zoo siab rau nws thiab mob siab rau coj cov kev kho mob tshiab rau cov neeg mob thoob ntiaj teb!"

Los ntawm lub hom phiaj ntawm cov tshuaj tiv thaiv kev puas tsuaj rau kev tshawb nrhiav lub platform, Hinova tuaj yeem tshuaj xyuas cov protein degradation sai sai thiab ua tiav cov qauv tsim thiab kev ua kom zoo ntawm chimeric degraders. Tsis tas li ntawd, Hinova muaj kev paub dhau los hauv kev tsim tshuaj lom neeg kev tswj hwm ntawm Chimeric degrader compounds.

Print Friendly, PDF & Email
Tsis muaj tus cim npe rau tshaj tawm no.